A Phase 1 interventional study of Acetaminophen/Naproxen Sodium in Orthodontic Pain, sponsored by Johnson & Johnson Consumer Inc. (J&JCI). Completed at 1 site in United States. Open to participants aged 12 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by Johnson & Johnson Consumer Inc. (J&JCI) (formerly part of Johnson & Johnson) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies testing acetaminophen in Pain — 5 open to participants now, 5 under way, none of them phase 3. Acetaminophen · Pain.
Among the 137 studies testing acetaminophen in Pain, this one is the 116th largest by enrollment, is one of 3 that started in 2023, is one of 11 in phase 1, and was the 126th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →5 of the 137 studies testing acetaminophen in Pain are open now, in 3 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Horizon Health Network · Sites in Canada
Ages 19+
University of Gaziantep · Sites in Turkey
Ages 18–75
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–45 · Women only · Healthy volunteers
Baskent University · Sites in Turkey
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 12 Years to 16 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 25 · Phase 4 67
First in 2003; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 95 across the 137 interventional studies. Of the 115 that completed or were terminated, 53 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 137 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Consumer Inc. (J&JCI), one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Consumer Inc. (J&JCI) is the lead sponsor of 55 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.
104 studies in Pain by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 99 finished, 32 (32%) have results posted.
Among the 104 studies in Pain by Johnson & Johnson, this one is the 73rd largest by enrollment of the 88 interventional ones that give a count, is one of 3 that started in 2023, is one of 10 in phase 1, and was the 102nd registered.
Johnson & Johnson’s Pain studies by the year they started, since 1986.
4 of the studies testing acetaminophen in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512297University of GaziantepPain Control During ESWL Using Non-Opioid Analgesics | 2027-01-01 |
| NCT07368738Horizon Health NetworkIntravenous Acetaminophen and Ketorolac for Pain Management During Extracorporeal Shockwave Lithotripsy | 2027-04 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07536425Western Galilee Hospital-NahariyaPreoperative Indomethacin and Paracetamol for Pain Management During Oocyte Retrieval in IVF Patients | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 137 studies testing acetaminophen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 104 in Pain:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the population pharmacokinetics of acetaminophen and naproxen from a novel acetaminophen /naproxen sodium fixed combination tablet in adolescents 12 to less than (\<) 17 years of age with post-procedure orthodontic pain and to describe the effect of subject-specific covariates, including age and body weight, on inter-subject variability in acetaminophen and naproxen pharmacokinetics in adolescents 12 to \<17 years of age with post-procedure orthodontic pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with age group 12 to less than (\<) 17 years who undergone a non-surgical orthodontic procedure will enroll and receive fixed dose combination of acetaminophen/naproxen sodium tablet orally on baseline (Day 0).
Drug: Acetaminophen/Naproxen Sodium
Drug pages: Acetaminophen · Naproxen
Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
Apparent Clearance (CL/F) of Acetaminophen/Naproxen Sodium
CL/F is defined as apparent clearance of acetaminophen/naproxen sodium.
Time frame: Pre-dose up to 48 hours post dose
Apparent Central Volume of Distribution (Vc/F) After Oral Dosing of Acetaminophen/Naproxen Sodium
Vc/F is defined as apparent central volume of distribution after oral dosing of acetaminophen/naproxen sodium.
Time frame: Pre-dose up to 48 hours post dose
Apparent Peripheral Volume of Distribution (Vp/F) After Oral Dosing of Acetaminophen/Naproxen Sodium
Vp/F is defined as apparent peripheral volume of distribution after oral dosing of acetaminophen/naproxen sodium.
Time frame: Pre-dose up to 48 hours post dose
Apparent Inter-compartmental Clearance (Q/F) of Acetaminophen/Naproxen Sodium
Q/F is defined as apparent inter-compartmental clearance of acetaminophen/naproxen sodium.
Time frame: Pre-dose up to 48 hours post dose
First-order Absorption Rate Constant (Ka) of Acetaminophen/Naproxen Sodium
Ka is defined as first-order absorption rate constant of acetaminophen/naproxen sodium.
Time frame: Pre-dose up to 48 hours post dose
Maximum Plasma Concentration (Cmax) of Acetaminophen/Naproxen Sodium
Cmax is defined as maximum plasma concentration of acetaminophen/naproxen sodium.
Time frame: Pre-dose up to 48 hours post dose
Time of occurrence of Maximum Plasma Concentration (Tmax) of Acetaminophen/Naproxen Sodium
Tmax is defined as time of occurrence of maximum plasma concentration of acetaminophen/naproxen sodium.
Time frame: Pre-dose up to 48 hours post dose
Area Under the Plasma Concentration versus Time Curve from Start of Drug Administration Until the Time of the Last Measurable Plasma Concentration (AUC[0-t])
AUC(0-t) is defined as area under the plasma concentration versus time curve from start of drug administration until the time of the last measurable plasma concentration of acetaminophen/naproxen sodium.
Time frame: Pre-dose up to 48 hours post dose
Area Under the Plasma Concentration versus Time Curve From Start of Drug Administration Until Infinity (AUC[0-infinite])
AUC(0-infinite) is defined as area under the plasma concentration versus time curve from start of drug administration until infinity of acetaminophen/naproxen sodium.
Time frame: Pre-dose up to 48 hours post dose
Terminal Elimination Rate Constant (lambda[z]) of Acetaminophen/Naproxen Sodium
Lambda(z) is defined as terminal elimination rate constant of acetaminophen/naproxen sodium.
Time frame: Pre-dose up to 48 hours post dose
Half Life (t1/2) of Acetaminophen/Naproxen Sodium
T1/2 is defined as half life of acetaminophen/naproxen sodium.
Time frame: Pre-dose up to 48 hours post dose
Number of Participants with Adverse Events (AEs)
An AE is any untoward medical occurrence that occurs in participants after they have signed an informed consent for the study. The event does not need to have a suspected causal relationship with the investigational product (IP).
Time frame: Up to 3 days
Plan to share: Yes — Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu
Data sharing details ↗ · yoda.yale.edu
Ran from Sep 2023 to primary completion in Feb 2024, 4 months.
Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 4 months is close to that.
Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetaminophen · Naproxen
Johnson & Johnson Consumer Inc. (J&JCI) →